Cancer Advisor | One Day MD

Abstract Background: Stage 4 prostate cancer has a 5-year survival rate of 37% with standard of care (SOC, e.g., androgen deprivation therapy [ADT], chemotherapy, Lu-177-PSMA-617). An optimized intervention combining repurposed drugs, supplements, diet/lifestyle, hyperthermia, and SOC components may improve outcomes. Methods : We simulated a double-blind RCT with 1,000 patients (500 per arm) with non-BRCA-mutated stage 4 prostate cancer (70% mHSPC, 30% mCRPC), comparing an integrative multimodal intervention arm (ivermectin 1.0–1.5 mg/kg/day (cycled 3 weeks on/1 off), mebendazole 500–1,500 mg/day (titrated), metformin 1,700 mg/day, vitamin C 1 g/kg IV 3 times/week, vitamin D 5,000 IU/day, curcumin 1,000 mg/day, low-glycemic Mediterranean diet, exercise, MBSR, hyperthermia [modulated electro-hyperthermia at 42°C for 60 minutes, 2–3 times weekly], plus ADT/Lu-177-PSMA-617) to a placebo arm with SOC. Primary endpoint was overall survival (OS); secondary endpoints included progression-fre...

Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: August 2026 Quick Answer No randomized controlled trial has shown that ivermectin, fenbendazole, or mebendazole cure colorectal cancer in humans. The strongest human evidence is a small, 40-patient randomized trial (Hegazy et al., 2022) in which mebendazole added to standard bevacizumab/FOLFOX4 chemotherapy improved response rates as an adjunct — not a replacement. In May 2026, the American Society of Clinical Oncology (ASCO) issued a formal Clinical Notice recommending against using ivermectin or fenbendazole for cancer treatment outside of a registered clinical trial, citing insufficient evidence and a real risk of toxicity and drug interactions. The hundreds of "case report" testimonials circulating on social media are self-reported, unverified, and not equivalent to clinical trial data. This article separates what is actually established from what is anecdo...

Introduction: Why This Debate Went Viral In 2026, a high-profile medical dispute spread across X (Twitter) and Substack involving two physicians with opposing views on the use of benzimidazole drugs —notably fenbendazole (veterinary dewormer) and mebendazole (human antiparasitic) —as potential cancer treatments. Naturopathic physician Dr. Colleen Huber, from her Arizona clinic, warned against using mebendazole and fenbendazole for cancer, calling it a risky fad that damages essential cell structures. Former physician William Makis countered with mebendazole's history since 1971, FDA approval for children as young as one, and his experience treating over 9,000 patients—though unverified. While lab studies show anticancer promise by disrupting tumor growth like some chemotherapies, human evidence is limited, fenbendazole remains veterinary-only with liver risks, and experts recommend sticking to proven treatments under medical guidance. ( X.com ) ...